{"disease":{"id":"effects-of-immunotherapy","name":"effects of immunotherapy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05885048","title":"Impact of Gonadotoxic Therapies on Fertility","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Michael von Wolff","has_results":false},{"nct_id":"NCT05420922","title":"Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT03388866","title":"Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Casa Espirita Terra de Ismael","has_results":false},{"nct_id":"NCT04813380","title":"Serum MicroRNAs 223 and 146a in Allergic Rhinitis Patients as Biomarkers for Efficacy of Sublingual Immunotherapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Zagazig University","has_results":false},{"nct_id":"NCT05098184","title":"A Study of GC101 TIL in Advanced Melanoma (10hospital)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT05087745","title":"A Clinical Study on TIL for the Treatment of Advanced Solid Tumors","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT05142475","title":"A Study of GC101 TIL in Advanced Breast Cancer (10hospital)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT05098171","title":"A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT05098197","title":"A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT03638375","title":"TIL and Anti-PD1 in Metastatic Melanoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":34,"lead_sponsor_name":"Leiden University","has_results":false},{"nct_id":"NCT06488950","title":"A Study of TIL in Advanced Solid Tumors (DFGD)","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT05468307","title":"A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Shanghai Juncell Therapeutics","has_results":false},{"nct_id":"NCT02169609","title":"Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Fundació Sant Joan de Déu","has_results":false},{"nct_id":"NCT02765243","title":"Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT02164461","title":"Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Advaxis, Inc.","has_results":true}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}